TLV · TEVA.TA
Teva Pharmaceutical Industries Limited
₪128.00+₪0.80 (+0.63%)
Teva Pharmaceutical Industries Limited’s quoted price sits in the upper half of its reported 52-week range, 2.07% below the high.
Loading market information…
OTC · ELTP · USD
Stock price, earnings
Quote as of Oct 30, 2026, 05:16 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Elite Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.81% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Elite Pharmaceuticals, Inc.’s next earnings report is currently expected on Nov 12, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Elite Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Elite Pharmaceuticals, Inc. (ELTP) is a specialized pharmaceutical company focused on the creation and manufacturing of generic medications, as well as oral, controlled-release drug formulations. Its business activities are primarily divided into two segments: Abbreviated New Drug Applications (ANDAs) for generic products and New Drug Applications (NDAs) for branded pharmaceuticals. The company's extensive product line includes drugs that it either owns, licenses, or produces through contract manufacturing. This portfolio features a variety of generic and oral-dose pharmaceutical products designed to address diverse medical needs. For instance, it offers Phentermine HCl 37.5mg tablets, marketed under the Adipex-P brand, and Phendimetrazine Tartrate 35mg tablets, known as Bontril, both utilized in bariatric medicine. Its offerings also extend to Naltrexone HCl 50mg tablets (Revia brand) for pain management, and Isradipine 2.5mg and 5mg capsules for cardiovascular conditions. Elite Pharmaceuticals further supplies various strengths of Oxycodone HCl immediate release tablets (5mg, 10mg, 15mg, 20mg, and 30mg) under the Roxycodone brand for pain relief, as well as Trimipramine Maleate Immediate Release antidepressant capsules (Surmontil brand). For central nervous system disorders, the company provides Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets, commonly associated with the Adderall brand. Additionally, its products include Dantrolene Sodium capsules (Dantrium brand) for muscle relaxation, SequestOX (an immediate-release Oxycodone formulation combined with Naltrexone), Loxapine Succinate capsules (Loxapine brand) for antipsychotic treatment, and a combination of Acetaminophen and Codeine Phosphate for managing mild to moderate pain, alongside various antibiotic products. Beyond its own product portfolio, Elite Pharmaceuticals also undertakes contract manufacturing of controlled-release products for external parties, covering therapeutic areas such as pain, allergies, bariatrics, and infections. The company is actively engaged in developing a new generation of opioid products specifically engineered to deter abuse. Established in 1997, Elite Pharmaceuticals, Inc. maintains its corporate headquarters in Northvale, New Jersey.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:33 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₪128.00+₪0.80 (+0.63%)
Teva Pharmaceutical Industries Limited’s quoted price sits in the upper half of its reported 52-week range, 2.07% below the high.
¥3,012+¥23 (+0.77%)
Shionogi & Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 19.85% below the high.
¥5,052+¥78 (+1.57%)
Eisai Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 3.64% below the high.
$21.39+$0.04 (+0.18%)
Amneal Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.34% below the high.
¥1,885-¥61 (-3.11%)
Sumitomo Pharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 42.69% below the high.
ZAR 158.00-ZAR 1.14 (-0.72%)
Aspen Pharmacare Holdings Limited’s quoted price sits in the upper half of its reported 52-week range, 4.94% below the high.
R$21.38-R$0.14 (-0.65%)
Hypera S.A.’s quoted price sits in the lower half of its reported 52-week range, 28.73% below the high.
$27.57+$0.64 (+2.36%)
Amphastar Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.62% below the high.
